An interventional study of Omnipod 5 and Multiple daily injections of insulin in Type 1 Diabetes, sponsored by Helsinki University Central Hospital. Recruiting at 2 sites in Finland. Open to participants aged 7 Years to 16 Years. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Helsinki University Central Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies in Diabetes Mellitus, Type 1 with a site in Finland — 8 open to participants now, 10 under way, 2 of them phase 3. Diabetes Mellitus, Type 1 · Finland.
Among the 66 studies in Diabetes Mellitus, Type 1 with a site in Finland, this one is the 41st largest by planned enrollment of the 53 interventional ones that give a count, is one of 3 that started in 2026, is one of 10 with no phase, and was the 66th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →8 of the 66 studies in Diabetes Mellitus, Type 1 with a site in Finland are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Finland, United States, Australia and 17 more countries
Ages 1–35
Eli Lilly and Company · Sites in Finland, United States, Australia and 16 more countries
Ages 1–35
SAb Biotherapeutics, Inc. · Sites in Finland, United States, Australia and 12 more countries
Ages 5–40
Turku University Hospital · Sites in Finland
Ages 18–45 · Women only · Healthy volunteers
University of South Florida · Sites in Finland, United States, Australia and 3 more countries
Ages 2–45 · Healthy volunteers
A study can be open while its sites in Finland have not opened yet or have stopped. Only those recruiting at a site in Finland →
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 7 Years to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
First in 1994; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 272 across the 53 interventional studies, 6,000 across the 13 observational. Of the 49 that completed or were terminated, 24 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 66 have an industry lead sponsor. The 10 most frequent:
Helsinki University Central Hospital is the lead sponsor of 311 studies on the registry; 61 are open to participants now.
Helsinki University Central Hospital has 5 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
2 of the studies in Diabetes Mellitus, Type 1 with a site in Finland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06111586SanofiFrexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS) | 2027-04-28 |
| NCT07187531SAb Biotherapeutics, Inc.SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 66 studies in Diabetes Mellitus, Type 1 with a site in Finland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the effect of early initiated automated insulin de-livery (AID) treatment in type diabetes in children aged 7-16 years to glycemic control, diabe-tes distress of patients and caregivers, long-term micro- and macrovascular complications and cost-effectiveness compared to multiple daily injections (MDI) and continuous glucose monitoring (CGM). The immediate costs of AID therapy are higher than costs of multiple daily injection therapy, and there has been debate whether the more expensive AID therapy is justified. No research on the cost-effectiveness of AID use in children has been conducted so far in Finland, and there is generally very little research data on the long-term treatment of type 1 diabetes with AID systems. AID therapy has been studied from the point of diagno-sis of type 1 diabetes in two centers (USA and the UK) but from the perspective of maintain-ing subject's own insulin secretion. A long-term randomized and controlled study on the out-comes and cost-effectiveness of AID therapy, started from diagnosis of diabetes, is essential to create evidence-based data for optimizing current treatment recommendations.
Our hypothesis is that AID treatment keeps the glycemic outcomes in targets in the long term and decreases diabetes distress. During longer time, AID system decreases the amount of micro- and macrovascular complications and is cost-effective treatment for children with type 1 diabetes (CwT1D).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Automated insulin delivery system (Omnipod 5) is initiated after T1D diagnosis. Omnipod5 uses a SmartAdjust™ closed-loop algorithm to automate insulin delivery. Algorithm continuously predicts glucose trends and self-adjusts insulin delivery within safety boundaries. Continious glucose monitoring (CGM) is used.
Device: Omnipod 5
Multiple daily insulin injections (MDI) is initiated after T1D with a standard treatment protocol. Continious glucose monitoring (CGM) is used.
Drug: Multiple daily injections of insulin
Omnipod5 uses a SmartAdjust™ closed-loop algorithm to automate insulin delivery. Algorithm continuously predicts glucose trends and self-adjusts insulin delivery within safety boundaries
Multiple daily infections of insulin to treat type 1 diabetes
Time in Range
Percentage (%) of the time patients' glucose levels are within the target range based on continuous glucose monitoring (time in range =TIR, 3.9-10 mmol/l).
Time frame: During the first 2 years
TINR
Time spent (%) in normoglycemic range (TINR, 3.9-7.8 mmol/l) based on continuous glucose monitorin (CGM) data
Time frame: During the first 2 years
Complications
The development of diabetes-related complications such as diabetic nephropathy, diabetic retinopathy, neuropathy, coronary artery disease
Time frame: 15 years
HbA1c
The change in HbA1c levels (mmol/mol) during the treatment between the groups
Time frame: 2 years
Mean sensor glucose value
The change in mean sensor glucose value (mmol/l) obtained from continuous glucose monitoring between the groups during treatment
Time frame: 2 years
Glycemic variability
The change in glycemic variability (coefficient of variation CV (SD/mean sensor glucose x 100%)) obtained from continuous glucose monitoring data between the groups during treatment
Time frame: 2 years
Continuous Ketone monitoring (CKM)
Continous Ketone monitoring with a CKM sensor will be performed at 2 time points during the follow-up period
Time frame: During the first 2 years
Cost-effectiveness
The cost-effectiveness of different treatment modalities for T1D in children with Cost-Utility Analysis modeling
Time frame: 15 years
Custom food list
The Custom Food List is a personalized menu integrated into the AID pump. Patients can select a predefined meal from the list before eating, without calculating the carbohydrate content, and the pump automatically delivers the preset insulin dose assigned to that item. We evaluated the impact of using the Custom Food List on Time in range (TIR, %), Time in Normoglycemic Range (TINR, %), Time below Range (TBR, %), and postprandial glucose levels compared with conventional carbohydrate counting.
Time frame: During the first 2 years
Plan to share: Undecided — Individual participant data will not be made publicly available. De-identified data may be shared upon reasonable request to the principal investigator, subject to applicable EU and Finnish data protection legislation and institutional approvals.
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Dec 2027, 16 months after the start.
Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 16 months is below that.
Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: start Apr 2026 → Aug 2026 and primary completion Sep 2027 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Helsinki University Central Hospital →